Historical perspectives on flavivirus research

Viruses

Volumn 9, Issue 5, 2017, Pages

  Holbrook, Michael R ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Dengue; Flavivirus; Japanese encephalitis; Tick borne encephalitis; West Nile; Yellow fever; Zika

Indexed keywords

DENGUE VACCINE; JAPANESE ENCEPHALITIS VACCINE; TICK BORNE ENCEPHALITIS VACCINE;

AEDES AEGYPTI; CULEX; DENGUE; FLAVIVIRUS INFECTION; HEMORRHAGIC FEVER; HEPATITIS; HUMAN; IMMUNIZATION; INFLAMMATION; JAPANESE ENCEPHALITIS; JAPANESE ENCEPHALITIS VIRUS; MOSQUITO VECTOR; NONHUMAN; ORGANISMS BY GEOGRAPHICAL DISTRIBUTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SEXUAL TRANSMISSION; TERMINALLY ILL PATIENT; TICK BORNE ENCEPHALITIS; TICK VECTOR; WEST NILE VIRUS; YELLOW FEVER; YELLOW FEVER VIRUS; ZIKA VIRUS; ANIMAL; DENGUE VIRUS; FLAVIVIRUS; HISTORY; IMMUNOLOGY; MEDICAL RESEARCH; MOSQUITO; PHYSIOLOGY; VIROLOGY; WEST NILE FEVER;

ANIMALS; BIOMEDICAL RESEARCH; CULICIDAE; DENGUE; DENGUE VIRUS; FLAVIVIRUS; FLAVIVIRUS INFECTIONS; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; WEST NILE FEVER; WEST NILE VIRUS; YELLOW FEVER; ZIKA VIRUS;

EID: 85019063610     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v9050097     Document Type: Review

References (165)

1. Pettersson, J.H., Fiz-Palacios, O. Dating the origin of the genus Flavivirus in the light of Beringian biogeography. J. Gen. Virol. 2014, 95, 1969-1982.
2. Westaway, E.G., Brinton, M.A., Gaidamovich, S., Horzinek, M.C., Igarashi, A., Kaariainen, L., Lvov, D.K., Porterfield, J.S., Russell, P.K., Trent, D.W. Flaviviridae. Intervirolgy 1985, 24, 183-192.
3. Blitvich, B.J., Firth, A.E. Insect-specific flaviviruses: A systematic review of their discovery, host range, mode of transmission, superinfection exclusion potential and genomic organization. Viruses 2015, 7, 1927-1959.
4. Carter, H.R. Yellow Fever, an Epidemiologicaland Historical Study of Its Place of Origin, William and Wilkins Company: Baltimore, MD, USA, 1931.
5. Garrison, F.H. An Introduction to the History of Medicine, 3rd ed., W.B. Saunders: Philadelphia, PA, USA, 1921.
6. Rush, B. Medical Inquiries and Observations, Thomas Dobson: Philadelphia, PA, USA, 1796, Volume 4.
7. Bloom, K.J. The Mississippi Valley's Great Yellow Fever Epidemic, Louisiana State University Press: Baton Rouge LA, USA, 1993, p. 296.
8. Finlay, C.J. The mosquito hypotheitically considered as the transmission agent of yellow fever (In Spanish). Anales de la Real Academia de Ciencias Medicas Fisicas y Naturales de la Habana 1881, 18, 147-169.
9. Finlay, C.J. The mosquito hypothetically considered as an agent in the transmission of yellow fever poison. New Orleans Med. Surg. J. 1881, 9, 601-616.
10. Reed, W., Carroll, J., Agramonte, A., Lazear, J.W. The etiology of yellow fever-A preliminary note. Public Health Pap. Rep. 1900, 26, 37-53.
11. Stokes, A., Bauer, J.H., Hudson, N.P. Experimental transmission of yellow fever to laboratory animals. Am. J. Trop. Med. 1928, 8, 103-164.
12. Monath, T.P., Barrett, A.D. Pathogenesis and pathophysiology of yellow fever. Adv. Virus Res. 2003, 60, 343-395.
13. Quaresma, J.A., Pagliari, C., Medeiros, D.B., Duarte, M.I., Vasconcelos, P.F. Immunity and immune response, pathology and pathologic changes: Progress and challenges in the immunopathology of yellow fever. Rev. Med. Virol. 2013, 23, 305-318.
14. Woodson, S.E., Freiberg, A.N., Holbrook, M.R. Differential cytokine responses from primary human Kupffer cells following infection with wild-type or vaccine strain yellow fever virus. Virology 2011, 412, 188-195.
15. Woodson, S.E., Freiberg, A.N., Holbrook, M.R. Coagulation factors, fibrinogen and plasminogen activator inhibitor-1, are differentially regulated by yellow fever virus infection of hepatocytes. Virus Res. 2013, 175, 155-159.
16. Woodson, S.E., Holbrook, M.R. Infection of hepatocytes with 17-D vaccine-strain yellow fever virus induces a strong pro-inflammatory host response. J. Gen. Virol. 2011, 92, 2262-2271.
17. Dennis, L.H., Reisberg, B.E., Crosbie, J., Crozier, D., Conrad, M.E. The original haemorrhagic fever: Yellow fever. Br. J. Haematol. 1969, 17, 455-462.
18. Monath, T.P., Brinker, K.R., Chandler, F.W., Kemp, G.E., Cropp, C.B. Pathophysiologic correlations in a rhesus monkey model of yellow fever with special observations on the acute necrosis of B cell areas of lymphoid tissues. Am. J. Trop. Med. Hyg. 1981, 30, 431-443.
19. Halstead, S.B. Reappearance of chikungunya, formerly called dengue, in the Americas. Emerg. Infect. Dis. 2015, 21, 557-561.
20. Pepper, O.H.P. A note on David Bylon and dengue. Ann. Med. Hist. 1941, 3, 363-368.
21. Chandler, A.C., Rice, L.M. Observations on the etiology of dengue fever. Am. J. Trop. Med. Hyg. 1923, 3, 233-262.
22. Siler, J.F. Dengue Fever. In The Georgraphy of Disease, McKinley, E.B., Ed., George Washington University Press: Washington, DC, USA, 1935, pp. 402-408.
23. Smart, W.R. On Dengue or Dandy Fever. Br. Med. J. 1877, 1, 382-383.
24. Bancroft, T.L. On the etiology of dengue fever. Australas. Med. Gaz. 1906, 25, 17-18.
25. Cleland, J.B., Bradley, B., Macdonald, W. Further Experiments in the Etiology of Dengue Fever. J. Hyg. 1919, 18, 217-254.
26. Cleland, J.B., Bradley, B., McDonald, W. On the transmission of Australian dengue by the mosquito Stegomyia faciata. Med. J. Aust. 1916, 11, 179-184.
27. Siler, J.F., Hall, M.W., Hitchens, A.P. Dengue. Philipp. J. Sci. 1926, 29, 1-304.
28. Ashburn, P.M., Craig, C.F. Experimental investigations regarding the etiology of dengue fever. J. Infect. Dis. 1907, 4, 440-475.
29. Simmons, J.S., St John, J.H., Reynolds, F.H.K. Experimental studies of dengue. Philipp. J. Sci. 1931, 44, 1-247.
30. Sabin, A.B. Dengue. In Viral and Rickettsial Infections of Man, 1st ed., Rivers, T.M., Ed., J.B. Lippincott: Philadelphia, PA, USA, 1948, pp. 445-453.
31. Carey, D.E. Use of a Combined Complement-Fixing Antigen to Detect Arthropod-Borne Viral Infection. Nature 1963, 200, 1024-1025.
32. Casals, J., Brown, L.V. Hemagglutination with arthropod-borne viruses. J. Exp. Med. 1954, 99, 429-449.
33. Sabin, A.B., Young, I. A complement fixation test for dengue. Proc. Soc. Exp. Biol. Med. 1948, 69, 478-480.
34. Sweet, B.H., Sabin, A.B. Properties and antigenic relationships of hemagglutinins associated with the dengue viruses. J. Immunol. 1954, 73, 363-373.
35. Vezza, A.C., Rosen, L., Repik, P., Dalrymple, J., Bishop, D.H. Characterization of the viral RNA species of prototype dengue viruses. Am. J. Trop. Med. Hyg. 1980, 29, 643-652.
36. Dunham, E.J., Holmes, E.C. Inferring the timescale of dengue virus evolution under realistic models of DNA substitution. J. Mol. Evol. 2007, 64, 656-661.
37. Tolou, H., Couissinier-Paris, P., Mercier, V., Pisano, M.R., de Lamballerie, X., de Micco, P., Durand, J.P. Complete genomic sequence of a dengue type 2 virus from the French West Indies. Biochem. Biophys. Res. Commun. 2000, 277, 89-92.
38. Zanotto, P.M., Gould, E.A., Gao, G.F., Harvey, P.H., Holmes, E.C. Population dynamics of flaviviruses revealed by molecular phylogenies. Proc. Natl. Acad. Sci. USA 1996, 93, 548-553.
39. Rico-Hesse, R. Molecular evolution and distribution of dengue viruses type 1 and 2 in nature. Virology 1990, 174, 479-493.
40. WHO, Dengue and severe dengue. Available online: http://www.who.int/mediacentre/factsheets/fs117/ en/ (accessed on 9 February 2017).
41. World Health Organization (WHO). Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control, World Health Organization: Geneva, Switzerland, 2009.
42. Sabin, A.B. Research on dengue during World War II. Am. J. Trop. Med. Hyg. 1952, 1, 30-50.
43. World Health Organization (WHO). Dengue Haemorrhagic Fever: Diagnosis, Prevention, Treatment and Control, World Health Organization: Geneva, Switzerland, 1997, pp. 1-84.
44. Jain, A., Chaturvedi, U.C. Dengue in infants: An overview. FEMS Immunol. Med. Microbiol. 2010, 59, 119-130.
45. Horstick, O., Martinez, E., Guzman, M.G., Martin, J.L., Ranzinger, S.R. WHO dengue case classification 2009 and its usefulness in practice: An expert consensus in the Americas. Pathog. Glob. Health 2015, 109, 19-25.
46. Screaton, G., Mongkolsapaya, J., Yacoub, S., Roberts, C. New insights into the immunopathology and control of dengue virus infection. Nat. Rev. Immunol. 2015, 15, 745-759.
47. Halstead, S.B. Dengue Antibody-Dependent Enhancement: Knowns and Unknowns. Microbiol. Spectr. 2014, 2.
48. Flipse, J., Wilschut, J., Smit, J.M. Molecular mechanisms involved in antibody-dependent enhancement of dengue virus infection in humans. Traffic 2013, 14, 25-35.
49. Castanha, P.M., Nascimento, E.J., Cynthia, B., Cordeiro, M.T., de Carvalho, O.V., de Mendonca, L.R., Azevedo, E.A., Franca, R.F., Rafael, D., Marques, E.T., Jr. Dengue virus (DENV)-specific antibodies enhance Brazilian Zika virus (ZIKV) infection. J. Infect. Dis. 2017, 215, 781-785.
50. Paul, L.M., Carlin, E.R., Jenkins, M.M., Tan, A.L., Barcellona, C.M., Nicholson, C.O., Michael, S.F., Isern, S. Dengue virus antibodies enhance Zika virus infection. Clin. Transl. Immunol. 2016, 5, e117.
51. Halstead, S.B., Jacobson, J. Japanese encephalitis. Adv. Virus Res. 2003, 61, 103-138.
52. Rosen, L. The natural history of Japanese encephalitis virus. Annu. Rev. Microbiol. 1986, 40, 395-414.
53. Mitamura, T., Kitaoka, M., Miura, T. On the geographical distribution of Japanese B encephalitis in the Far East Asia. Jpn. Med. J. 1950, 3, 257-264.
54. Solomon, T., Ni, H., Beasley, D.W., Ekkelenkamp, M., Cardosa, M.J., Barrett, A.D. Origin and evolution of Japanese encephalitis virus in southeast Asia. J. Virol. 2003, 77, 3091-3098.
55. Li, M.H., Fu, S.H., Chen, W.X., Wang, H.Y., Guo, Y.H., Liu, Q.Y., Li, Y.X., Luo, H.M., Da, W., Duo Ji, D.Z., et al. Genotype V Japanese encephalitis virus is emerging. PLoS Negl. Trop. Dis. 2011, 5, e1231.
56. Mohammed, M.A., Galbraith, S.E., Radford, A.D., Dove, W., Takasaki, T., Kurane, I., Solomon, T. Molecular phylogenetic and evolutionary analyses of Muar strain of Japanese encephalitis virus reveal it is the missing fifth genotype. Infect. Genet. Evol. 2011, 11, 855-862.
57. Takhampunya, R., Kim, H.C., Tippayachai, B., Kengluecha, A., Klein, T.A., Lee, W.J., Grieco, J., Evans, B.P. Emergence of Japanese encephalitis virus genotype V in the Republic of Korea. Virol. J. 2011, 8, 449.
58. Erlanger, T.E., Weiss, S., Keiser, J., Utzinger, J., Wiedenmayer, K. Past, present, and future of Japanese encephalitis. Emerg. Infect. Dis. 2009, 15, 1-7.
59. World Health Organization (WHO). Japanese Encephalitis Vaccines: WHO position paper, February 2015—Recommendations. Vaccine 2016, 34, 302-303.
60. Campbell, G.L., Hills, S.L., Fischer, M., Jacobson, J.A., Hoke, C.H., Hombach, J.M., Marfin, A.A., Solomon, T., Tsai, T.F., Tsu, V.D., et al. Estimated global incidence of Japanese encephalitis: A systematic review. Bull. World Health Organ. 2011, 89, 766-774.
61. Weaver, S.C., Barrett, A.D. Transmission cycles, host range, evolution and emergence of arboviral disease. Nat. Rev. Microbiol. 2004, 2, 789-801.
62. Le Flohic, G., Porphyre, V., Barbazan, P., Gonzalez, J.P. Review of climate, landscape, and viral genetics as drivers of the Japanese encephalitis virus ecology. PLoS Negl. Trop. Dis. 2013, 7, e2208.
63. Griffiths, M.J., Turtle, L., Solomon, T. Japanese encephalitis virus infection. Handb. Clin. Neurol. 2014, 123, 561-576.
64. Yun, S.I., Lee, Y.M. Japanese encephalitis: The virus and vaccines. Hum. Vaccine Immunother. 2014, 10, 263-279.
65. Zilber, L.A., Soloviev, V.D. Far eastern tick-borne spring-summer (spring) encephalitis. Am. Rev. Sov. Med. 1946, 3, 1-75.
66. Smorodintsev, A.A. Tick-borne spring-summer encephalitis. Prog. Med. Virol. 1958, 1, 210-248.
67. Smorodintsev, A.A., Kagan, N.W., Levkovitsch, E.N., Dankovskij, N.L. Experimenteller und epidemiologischer Beitrag zur activen Immunisierung gegen die Fruhling-Sommer-zecken-encephalitis. Arch. Ges. Virusforsch. 1941, 2, 1-25.
68. Calisher, C.H. Antigenic classification and taxonomy of flaviviruses (family Flaviviridae) emphasizing a universal system for the taxonomy of viruses causing tick-borne encephalitis. Acta Virol. 1988, 32, 469-478.
69. Zanotto, P.M., Gao, G.F., Gritsun, T., Marin, M.S., Jiang, W.R., Venugopal, K., Reid, H.W., Gould, E.A. An arbovirus cline across the northern hemisphere. Virology 1995, 210, 152-159.
70. Fauquet, C.M., Mayo, M.A., Maniloff, J., Desselberger, U., Ball, L.A. Virus Taxonomy: VIIIth Report of the International Committee on Taxonomy of Viruses, Elsevier Academic Press: San Diego, CA, USA, 2005.
71. Slovak, M., Kazimirova, M., Siebenstichova, M., Ustanikova, K., Klempa, B., Gritsun, T., Gould, E.A., Nuttall, P.A. Survival dynamics of tick-borne encephalitis virus in Ixodes ricinus ticks. Ticks Tick-Borne Dis. 2014, 5, 962-969.
72. Randolph, S.E. Transmission of tick-borne pathogens between co-feeding ticks: Milan Labuda's enduring paradigm. Ticks Tick-Borne Dis. 2011, 2, 179-182.
73. Mlera, L., Meade-White, K., Saturday, G., Scott, D., Bloom, M.E. Modeling Powassan virus infection in Peromyscus leucopus, a natural host. PLoS Negl. Trop. Dis. 2017, 11, e0005346.
74. Clarke, D.H., Casals, J. Arboviruses: Group B. In Viral and Rickettsial Infections of Man, 4th ed., Horsfall, F.L., Jr., Tamm, I., Eds., J.B. Lippincott: Philadelphia, PA, USA, 1965.
75. Ruzek, D., Dobler, G., Donoso Mantke, O. Tick-borne encephalitis: Pathogenesis and clinical implications. Travel Med. Infect. Dis. 2010, 8, 223-232.
76. Gritsun, T.S., Lashkevich, V.A., Gould, E.A. Tick-borne encephalitis. Antivir. Res. 2003, 57, 129-146.
77. Bodemann, H.H., Pausch, J., Schmitz, H., Hoppe-Seyler, G. Tick-born encephalitis (ESME) as laboratory infection. Die Med. Welt 1977, 28, 1779-1781.
78. Gritsun, T.S., Nuttall, P.A., Gould, E.A. Tick-borne flaviviruses. Adv. Virus Res. 2003, 61, 317-371.
79. Pogodina, V.V., Frolova, M.P., Malenko, G.V., Fokina, G.I., Levina, L.S., Mamonenko, L.L., Koreshkova, G.V., Ralf, N.M. Persistence of tick-borne encephalitis virus in monkeys. I. Features of experimental infection. Acta Virol. 1981, 25, 337-343.
80. Pogodina, V.V., Levina, L.S., Fokina, G.I., Koreshkova, G.V., Malenko, G.V., Bochkova, N.G., Rzhakhova, O.E. Persistence of tic-borne encephalitis virus in monkeys. III. Phenotypes of the persisting virus. Acta Virol. 1981, 25, 352-360.
81. Pogodina, V.V., Malenko, G.V., Fokina, G.I., Levina, L.S., Koreshkova, G.V., Rzhakhova, O.E., Bochkova, N.G., Mamonenko, L.L. Persistence of tick-borne encephalitis virus in monkeys. II. Effectiveness of methods used for virus detection. Acta Virol. 1981, 25, 344-351.
82. Poponnikova, T.V. Specific clinical and epidemiological features of tick-borne encephalitis in Western Siberia. Int. J. Med. Microbiol. IJMM 2006, 296 (Suppl 40), 59-62.
83. Ruzek, D., Yakimenko, V.V., Karan, L.S., Tkachev, S.E. Omsk haemorrhagic fever. Lancet 2010, 376, 2104-2113.
84. Sadanandane, C., Elango, A., Marja, N., Sasidharan, P.V., Raju, K.H., Jambulingam, P. An outbreak of Kyasanur forest disease in the Wayanad and Malappuram districts of Kerala, India. Ticks Tick-Borne Dis. 2017, 8, 25-30.
85. Memish, Z.A., Fagbo, S.F., Osman Ali, A., AlHakeem, R., Elnagi, F.M., Bamgboye, E.A. Is the epidemiology of alkhurma hemorrhagic fever changing?: A three-year overview in Saudi Arabia. PLoS ONE 2014, 9, e85564.
86. Briese, T., Jia, X.Y., Huang, C., Grady, L.J., Lipkin, W.I. Identification of a Kunjin/West Nile-like Flavivirus in brains of patients with New York encephalitis. Lancet 1999, 354, 1261-1262.
87. Murray, K.O., Mertens, E., Despres, P. West Nile virus and its emergence in the United States of America. Vet. Res. 2010, 41, 67.
88. Nikolay, B. A review of West Nile and Usutu virus co-circulation in Europe: How much do transmission cycles overlap? Trans. R. Soc. Trop. Med. Hyg. 2015, 109, 609-618.
89. Chancey, C., Grinev, A., Volkova, E., Rios, M. The global ecology and epidemiology of West Nile virus. Biomed. Res. Int. 2015, 2015, 376230.
90. Kilpatrick, A.M. Globalization, land use, and the invasion of West Nile virus. Science 2011, 334, 323-327.
91. Hinten, S.R., Beckett, G.A., Gensheimer, K.F., Pritchard, E., Courtney, T.M., Sears, S.D., Woytowicz, J.M., Preston, D.G., Smith, R.P., Jr., Rand, P.W., et al. Increased recognition of Powassan encephalitis in the United States, 1999-2005. Vector-Borne Zoonotic Dis. 2008, 8, 733-740.
92. Ramos, M.M., Mohammed, H., Zielinski-Gutierrez, E., Hayden, M.H., Lopez, J.L., Fournier, M., Trujillo, A.R., Burton, R., Brunkard, J.M., Anaya-Lopez, L., et al. Epidemic dengue and dengue hemorrhagic fever at the Texas-Mexico border: Results of a household-based seroepidemiologic survey, December 2005. Am. J. Trop. Med. Hyg. 2008, 78, 364-369.
93. Thomas, D.L., Santiago, G.A., Abeyta, R., Hinojosa, S., Torres-Velasquez, B., Adam, J.K., Evert, N., Caraballo, E., Hunsperger, E., Munoz-Jordan, J.L., et al. Reemergence of dengue in Southern Texas, 2013. Emerg. Infect. Dis. 2016, 22, 1002-1007.
94. Adalja, A.A., Sell, T.K., Bouri, N., Franco, C. Lessons learned during dengue outbreaks in the United States, 2001-2011. Emerg. Infect. Dis. 2012, 18, 608-614.
95. Effler, P.V., Pang, L., Kitsutani, P., Vorndam, V., Nakata, M., Ayers, T., Elm, J., Tom, T., Reiter, P., Rigau-Perez, J.G., et al. Dengue fever, Hawaii, 2001-2002. Emerg. Infect. Dis. 2005, 11, 742-749.
96. Johnston, D., Viray, M., Ushiroda, J., Whelen, A.C., Sciulli, R., Gose, R., Lee, R., Honda, E., Park, S.Y., Hawaii dengue response, T. Notes from the field: Outbreak of locally acquired cases of dengue fever—Hawaii, 2015. MMWR Morb. Mortal. Wkly. Rep. 2016, 65, 34-35.
97. Murray, K.O., Rodriguez, L.F., Herrington, E., Kharat, V., Vasilakis, N., Walker, C., Turner, C., Khuwaja, S., Arafat, R., Weaver, S.C., et al. Identification of dengue fever cases in Houston, Texas, with evidence of autochthonous transmission between 2003 and 2005. Vector-Borne Zoonotic Dis. 2013, 13, 835-845.
98. Weissenbock, H., Kolodziejek, J., Url, A., Lussy, H., Rebel-Bauder, B., Nowotny, N. Emergence of Usutu virus, an African mosquito-borne Flavivirus of the Japanese encephalitis virus group, central Europe. Emerg. Infect. Dis. 2002, 8, 652-656.
99. Ashraf, U., Ye, J., Ruan, X., Wan, S., Zhu, B., Cao, S. Usutu virus: An emerging Flavivirus in Europe. Viruses 2015, 7, 219-238.
100. Cadar, D., Luhken, R., van der Jeugd, H., Garigliany, M., Ziegler, U., Keller, M., Lahoreau, J., Lachmann, L., Becker, N., Kik, M., et al. Widespread activity of multiple lineages of Usutu virus, western Europe, 2016. Euro Surveill 2017, 22.
101. Grottola, A., Marcacci, M., Tagliazucchi, S., Gennari, W., Di Gennaro, A., Orsini, M., Monaco, F., Marchegiano, P., Marini, V., Meacci, M., et al. Usutu virus infections in humans: A retrospective analysis in the municipality of Modena, Italy. Clin. Microbiol. Infect. 2017, 23, 33-37.
102. Woodall, J.P. The viruses isolated from arthropods at the East African virus research institute in the 26 years ending December 1963. Proc. E Afr. Acad. 1964, 2, 141-146.
103. Theiler, M., Smith, H.H. The use of yellow fever virus modified by in vitro cultivation for human immunization. J. Exp. Med. 1937, 65, 787-800.
104. Beck, A.S., Barrett, A.D. Current status and future prospects of yellow fever vaccines. Expert Rev. Vaccines 2015, 14, 1479-1492.
105. Staples, J.E., Bocchini, J.A., Jr., Rubin, L., Fischer, M., Centers for Disease Control and Prevention (CDC). Yellow fever vaccine booster doses: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb. Mortal. Wkly. Rep. 2015, 64, 647-650.
106. Mason, R.A., Tauraso, N.M., Spertzel, R.O., Ginn, R.K. Yellow fever vaccine: Direct challenge of monkeys given graded doses of 17D vaccine. Appl. Microbiol. 1973, 25, 539-544.
107. Seligman, S.J. Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD). Vaccine 2014, 32, 5769-5775.
108. Thomas, R.E. Yellow fever vaccine-associated viscerotropic disease: Current perspectives. Drug Des. Dev. Ther. 2016, 10, 3345-3353.
109. Bassi, M.R., Larsen, M.A., Kongsgaard, M., Rasmussen, M., Buus, S., Stryhn, A., Thomsen, A.R., Christensen, J.P. Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice. PLoS Negl. Trop. Dis. 2016, 10, e0004464.
110. Schafer, B., Holzer, G.W., Joachimsthaler, A., Coulibaly, S., Schwendinger, M., Crowe, B.A., Kreil, T.R., Barrett, P.N., Falkner, F.G. Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever. PLoS ONE 2011, 6, e24505.
111. Maciel, M., Jr., Cruz Fda, S., Cordeiro, M.T., da Motta, M.A., Cassemiro, K.M., Maia Rde, C., de Figueiredo, R.C., Galler, R., Freire Mda, S., August, J.T., et al. A DNA vaccine against yellow fever virus: Development and evaluation. PLoS Negl. Trop. Dis. 2015, 9, e0003693.
112. Tretyakova, I., Nickols, B., Hidajat, R., Jokinen, J., Lukashevich, I.S., Pushko, P. Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice. Virology 2014, 468-470, 28-35.
113. Pereira, R.C., Silva, A.N., Souza, M.C., Silva, M.V., Neves, P.P., Silva, A.A., Matos, D.D., Herrera, M.A., Yamamura, A.M., Freire, M.S., et al. An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures. Vaccine 2015, 33, 4261-4268.
114. Hoke, C.H., Nisalak, A., Sangawhipa, N., Jatanasen, S., Laorakapongse, T., Innis, B.L., Kotchasenee, S., Gingrich, J.B., Latendresse, J., Fukai, K., et al. Protection against Japanese encephalitis by inactivated vaccines. N. Engl. J. Med. 1988, 319, 608-614.
115. Igarashi, H. Control of Japanese encephalitis in Japan: Immunization of humans and animals, and vector control. In Japanese Encephalitis and West Nile Viruses, Mackenzie, J., Barrett, A.D.T., Deubel, V., Eds., Springer: Berlin, Germany, 2002, pp. 139-152.
116. Chumakov, M.P., Gagarina, A.V., Vilner, L.M., Khanina, M.K., Rodin, I.M., Vasenovich, M.I., Lakina, V.I., Finogenova, E.V. Experience in the Experimental Production and Control of Tissue Culture Vaccine against Tick Encephalitis. Vopr. Virusol. 1963, 29, 415-420.
117. Kunz, C. TBE vaccination and the Austrian experience. Vaccine 2003, 21, S50-S55.
118. Girgsdies, O.E., Rosenkranz, G. Tick-borne encephalitis: Development of a paediatric vaccine. A controlled, randomized, double-blind and multicentre study. Vaccine 1996, 14, 1421-1428.
119. Lehrer, A.T., Holbrook, M.R. Tick-borne encephalitis vaccines. In Vaccines for Biodefense and Emerging and Neglected Diseases, Barrett, A.D.T., Stanberry, L.R., Eds., Academic Press: London, UK, 2009, pp. 713-718.
120. Zent, O., Broker, M. Tick-borne encephalitis vaccines: Past and present. Expert Rev. Vaccines 2005, 4, 747-755.
121. Coudeville, L., Baurin, N., L’Azou, M., Guy, B. Potential impact of dengue vaccination: Insights from two large-scale phase III trials with a tetravalent dengue vaccine. Vaccine 2016, 34, 6426-6435.
122. Coudeville, L., Baurin, N., Vergu, E. Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies. Vaccine 2016, 34, 6417-6425.
123. Guy, B., Barrere, B., Malinowski, C., Saville, M., Teyssou, R., Lang, J. From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011, 29, 7229-7241.
124. McArthur, M.A., Sztein, M.B., Edelman, R. Dengue vaccines: Recent developments, ongoing challenges and current candidates. Expert Rev. Vaccines 2013, 12, 933-953.
125. Scott, L.J. Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease. Drugs 2016, 76, 1301-1312.
126. Anonymous. Dengue vaccine: WHO position paper—July 2016. Wkly. Epidemiol. Rec. 2016, 91, 349-364.
127. Halstead, S.B., Russell, P.K. Protective and immunological behavior of chimeric yellow fever dengue vaccine. Vaccine 2016, 34, 1643-1647.
128. Huang, C.Y., Butrapet, S., Tsuchiya, K.R., Bhamarapravati, N., Gubler, D.J., Kinney, R.M. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J. Virol. 2003, 77, 11436-11447.
129. Osorio, J.E., Huang, C.Y., Kinney, R.M., Stinchcomb, D.T. Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine 2011, 29, 7251-7260.
130. Osorio, J.E., Velez, I.D., Thomson, C., Lopez, L., Jimenez, A., Haller, A.A., Silengo, S., Scott, J., Boroughs, K.L., Stovall, J.L., et al. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: A randomised, placebo-controlled, phase 1 study. Lancet Infect. Dis. 2014, 14, 830-838.
131. Osorio, J.E., Partidos, C.D., Wallace, D., Stinchcomb, D.T. Development of a recombinant, chimeric tetravalent dengue vaccine candidate. Vaccine 2015, 33, 7112-7120.
132. Whitehead, S.S. Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine, what makes this vaccine different from the Sanofi-Pasteur CYD vaccine? Expert Rev. Vaccines 2016, 15, 509-517.
133. Lindow, J.C., Durbin, A.P., Whitehead, S.S., Pierce, K.K., Carmolli, M.P., Kirkpatrick, B.D. Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles. Vaccine 2013, 31, 3347-3352.
134. Kirkpatrick, B.D., Whitehead, S.S., Pierce, K.K., Tibery, C.M., Grier, P.L., Hynes, N.A., Larsson, C.J., Sabundayo, B.P., Talaat, K.R., Janiak, A., et al. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model. Sci. Transl. Med. 2016, 8, 330ra36.
135. Kirkpatrick, B.D., Durbin, A.P., Pierce, K.K., Carmolli, M.P., Tibery, C.M., Grier, P.L., Hynes, N., Diehl, S.A., Elwood, D., Jarvis, A.P., et al. Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults. J. Infect. Dis. 2015, 212, 702-710.
136. Thomas, S.J., Rothman, A.L. Trials and Tribulations on the Path to Developing a Dengue Vaccine. Am. J. Prev. Med. 2015, 49 (Suppl 4), S334-S344.
137. Thomas, S.J. Developing a dengue vaccine: Progress and future challenges. Ann. N. Y. Acad. Sci. 2014, 1323, 140-159.
138. Kroschewski, H., Allison, S.L., Heinz, F.X., Mandl, C.W. Role of heparan sulfate for attachment and entry of tick-borne encephalitis virus. Virology 2003, 308, 92-100.
139. Liu, P., Ridilla, M., Patel, P., Betts, L., Gallichotte, E., Shahidi, L., Thompson, N.L., Jacobson, K. Beyond attachment: Roles of DC-SIGN in dengue virus infection. Traffic 2017, 18, 218-231.
140. Fernandez-Garcia, M.D., Meertens, L., Chazal, M., Hafirassou, M.L., Dejarnac, O., Zamborlini, A., Despres, P., Sauvonnet, N., Arenzana-Seisdedos, F., Jouvenet, N., et al. Vaccine and wild-type strains of yellow fever virus engage distinct entry mechanisms and differentially stimulate antiviral immune responses. mBio 2016, 7, e01956-15.
141. Netland, J., Bevan, M.J. CD8 and CD4 T cells in west nile virus immunity and pathogenesis. Viruses 2013, 5, 2573-2584.
142. Wang, T., Welte, T. Role of natural killer and Gamma-delta T cells in West Nile virus infection. Viruses 2013, 5, 2298-2310.
143. Aberle, J.H., Schwaiger, J., Aberle, S.W., Stiasny, K., Scheinost, O., Kundi, M., Chmelik, V., Heinz, F.X. Human CD4+ T Helper Cell Responses after Tick-Borne Encephalitis Vaccination and Infection. PLoS ONE 2015, 10, e0140545.
144. Blom, K., Braun, M., Pakalniene, J., Dailidyte, L., Beziat, V., Lampen, M.H., Klingstrom, J., Lagerqvist, N., Kjerstadius, T., Michaelsson, J., et al. Specificity and dynamics of effector and memory CD8 T cell responses in human tick-borne encephalitis virus infection. PLoS Pathog. 2015, 11, e1004622.
145. 8+ T-cells mediate immunopathology in tick-borne encephalitis. Virology 2009, 384, 1-6.
146. Ahmed, R., Akondy, R.S. Insights into human CD8(+) T-cell memory using the yellow fever and smallpox vaccines. Immunol. Cell Biol. 2011, 89, 340-345.
147. Wieten, R.W., Goorhuis, A., Jonker, E.F., de Bree, G.J., de Visser, A.W., van Genderen, P.J., Remmerswaal, E.B., Ten Berge, I.J., Visser, L.G., Grobusch, M.P., et al. 17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients. J. Infect. 2016, 72, 713-722.
148. Wieten, R.W., Jonker, E.F., van Leeuwen, E.M., Remmerswaal, E.B., Ten Berge, I.J., de Visser, A.W., van Genderen, P.J., Goorhuis, A., Visser, L.G., Grobusch, M.P., et al. A single 17D yellow fever vaccination provides lifelong immunity, characterization of yellow-fever-specific neutralizing antibody and T-cell responses after vaccination. PLoS ONE 2016, 11, e0149871.
149. Holbrook, M.R., Gowen, B.B. Animal models of highly pathogenic RNA viral infections: Encephalitis viruses. Antivir. Res. 2008, 78, 69-78.
150. Kenyon, R.H., Rippy, M.K., McKee, K.T., Jr., Zack, P.M., Peters, C.J. Infection of Macaca radiata with viruses of the tick-borne encephalitis group. Microb. Pathog. 1992, 13, 399-409.
151. McArthur, M.A., Suderman, M.T., Mutebi, J.P., Xiao, S.Y., Barrett, A.D. Molecular characterization of a hamster viscerotropic strain of yellow fever virus. J. Virol. 2003, 77, 1462-1468.
152. Tesh, R.B., Guzman, H., da Rosa, A.P., Vasconcelos, P.F., Dias, L.B., Bunnell, J.E., Zhang, H., Xiao, S.Y. Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies. J. Infect. Dis. 2001, 183, 1431-1436.
153. Meier, K.C., Gardner, C.L., Khoretonenko, M.V., Klimstra, W.B., Ryman, K.D. A mouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathog. 2009, 5, e1000614.
154. Watson, A.M., Lam, L.K., Klimstra, W.B., Ryman, K.D. The 17D-204 vaccine strain-induced protection against virulent yellow fever virus is mediated by humoral immunity and CD4+ but not CD8+ T cells. PLoS Pathog. 2016, 12, e1005786.
155. Sarathy, V.V., Milligan, G.N., Bourne, N., Barrett, A.D. Mouse models of dengue virus infection for vaccine testing. Vaccine 2015, 33, 7051-7060.
156. Chan, K.W., Watanabe, S., Kavishna, R., Alonso, S., Vasudevan, S.G. Animal models for studying dengue pathogenesis and therapy. Antivir. Res. 2015, 123, 5-14.
157. Foy, B.D., Kobylinski, K.C., Chilson Foy, J.L., Blitvich, B.J., Travassos da Rosa, A., Haddow, A.D., Lanciotti, R.S., Tesh, R.B. Probable non-vector-borne transmission of Zika virus, Colorado, USA. Emerg. Infect. Dis. 2011, 17, 880-882.
158. Moreira, J., Peixoto, T.M., Machado de Siqueira, A., Lamas, C.C. Sexually acquired Zika virus: A systematic review. Clin. Microbiol. Infect. 2017.
159. Tabata, T., Petitt, M., Puerta-Guardo, H., Michlmayr, D., Wang, C., Fang-Hoover, J., Harris, E., Pereira, L. Zika virus targets different primary human placental cells, suggesting two routes for vertical transmission. Cell Host Microbe 2016, 20, 155-166.
160. Alpert, S.G., Fergerson, J., Noel, L.P. Intrauterine West Nile virus: Ocular and systemic findings. Am. J. Ophthalmol. 2003, 136, 733-735.
161. O’Leary, D.R., Kuhn, S., Kniss, K.L., Hinckley, A.F., Rasmussen, S.A., Pape, W.J., Kightlinger, L.K., Beecham, B.D., Miller, T.K., Neitzel, D.F., et al. Birth outcomes following West Nile Virus infection of pregnant women in the United States: 2003-2004. Pediatrics 2006, 117, e537-e545.
162. Colt, S., Garcia-Casal, M.N., Pena-Rosas, J.P., Finkelstein, J.L., Rayco-Solon, P., Weise Prinzo, Z.C., Mehta, S. Transmission of Zika virus through breast milk and other breastfeeding-related bodily-fluids: A systematic review. PLoS Negl. Trop. Dis. 2017, 11, e0005528.
163. Anonymous. From the Centers for Disease Control and Prevention. Possible West Nile virus transmission to an infant through breast-feeding—Michigan, 2002. JAMA 2002, 288, 1976-1977.
164. Barthel, A., Gourinat, A.C., Cazorla, C., Joubert, C., Dupont-Rouzeyrol, M., Descloux, E. Breast milk as a possible route of vertical transmission of dengue virus? Clin. Infect. Dis. 2013, 57, 415-417.
165. Kuhn, S., Twele-Montecinos, L., MacDonald, J., Webster, P., Law, B. Case report: Probable transmission of vaccine strain of yellow fever virus to an infant via breast milk. CMAJ 2011, 183, E243-E245.